Audited Financial Results for the quarter and year ended 31st March 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Chemcrux Enterprises reported a noticeable drop in FY25 performance on a standalone basis. Revenue from operations fell to Rs 7,025.39 lacs from Rs 7,846.53 lacs in FY24, a decline of about 10.5%. Profit after tax nearly halved to Rs 418.86 lacs versus Rs 844.43 lacs in the previous year. On a consolidated basis, profit came in at Rs 391.36 lacs (vs Rs 844.43 lacs). Q4 standalone revenue was Rs 1,596.56 lacs and PAT was Rs 47.45 lacs, down sharply YoY. The Board recommended a final dividend of 10% (Rs 1 per share). During Q4, Chemcrux acquired the remaining 50% stake in Kalichem Private Limited, making it a wholly-owned subsidiary. The statutory auditor (Naresh & Co.) issued an unmodified opinion on both standalone and consolidated results.
The sharp fall in profits, despite revenue holding up better, points to margin compression which may weigh on near-term sentiment. However, the unchanged dividend and the acquisition consolidating Kalichem as a wholly-owned subsidiary are positives that could support the stock over the longer term.